<DOC>
	<DOC>NCT00122330</DOC>
	<brief_summary>The primary objective is to evaluate the safety and efficacy of eculizumab in transfusion dependent patients with hemolytic PNH.</brief_summary>
	<brief_title>Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Must have required at least 4 transfusions in the past 12 months PNH type III red blood cell (RBC) clone by flow cytometry of &gt;10% Lactate dehydrogenase (LDH) level &gt; 1.5 x upper limit of normal Platelet count &gt; 100,000/mm3 Patient taking erythropoietin must be on a stable dose for at least 26 weeks Patient taking immunosuppressants must be on a stable dose for at least 26 weeks Patient taking corticosteroids must be on a stable dose for at least 4 weeks Patient taking coumadin must be at a stable INR for at least 4 weeks Patient taking iron supplements or folic acid must be on a stable dose for 4 weeks Willing and able to give written informed consent Must avoid conception Mean hemoglobin level prior to transfusion over the previous 12 months is &gt;10.5 gm/dl Absolute neutrophil count &lt;500/ul Active bacterial infection Hereditary complement deficiency Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedures within 30 days Pregnant, breastfeeding, or intending to conceive History of meningococcal disease History of bone marrow transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>